BioMagnetic Solutions will build a ferrofluid and monoclonal antibody production facility at Innovation Park in Pennsylvania, US.   Gamma Biosciences acquired cell selection and bioseparation firm BioMagnetic Solutions (BMS) in January. Now BMS will construct a 13,000 square-foot production facility in Innovation Park at Penn State, which is expected to be fully operation in mid-2022. BMS claims the company will continue to focus on developing proprietary nanoscale ferrofluids from clinical to development through to commercial scale and the facility will…